Clinical Trials for Brain Tumor

A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CNS tumors receiving radiotherapy: recurrent/relapsed GBM (IMRT 35 Gy/2 weeks) and newly diagnosed GBM with unmethylated MGMT (IMRT 60 Gy/6 weeks) are treated with concurrent oral AZD1390, a brain-penetrant ATM kinase inhibitor radiosensitizer; the closed arm previously enrolled patients with brain metastases not suitable for SRS. Key eligibility includes KPS ≥60 and MRI suitability; exclusions include strong CYP3A4 modulators and significant comorbidities.

ClinicalTrials.gov ID: NCT03423628

PEACH TRIAL- Precision mEdicine and Adoptive Cellular tHerapy for the Treatment of Recurrent Neuroblastoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Children and young adults with newly diagnosed DIPG/brainstem glioma (pre‑radiation, biopsy‑amenable) or relapsed/refractory high‑risk neuroblastoma receive autologous tumor‑reactive T cells (TTRNA‑xALT), generated by priming patient T cells with total tumor RNA–loaded dendritic cells to create a broad, personalized antitumor T‑cell repertoire. Dose‑escalated infusions (3×10^6–3×10^8 cells/kg) assess safety/MTD, with manufacturing feasibility and clinical activity as secondary endpoints.

ClinicalTrials.gov ID: NCT04837547